June 20, 2018
FDA letter updates risks of Type III endoleaks with aortic endovascular graft systems
Editor's Note
In a June 19 letter to healthcare providers, the Food & Drug Administration (FDA) says it continues to evaluate information from several sources, including manufacturers, on the risks associated with Type III endoleaks with various endovascular graft systems used for treatment of abdominal aortic aneurysms (AAAs) and aorto-iliac aneurysms.
Based on new information, the FDA says the Endologix AFX with Strata device is at greater risk for Type III endoleaks than other endovascular AAA graft systems.
Free Daily News
- HFMA warns affordability crisis is driving up provider bad debt
- Report warns sterile processing staffing crisis threatens surgical safety
- Ascension swings to profit as outpatient push, cost cuts take hold
- High BMI alone did not raise early complication risk after outpatient TJA
- AAAHC report spotlights top accreditation deficiencies, strategies for safer ambulatory care
- ACS conference charts bold future for surgical quality with data, teamwork, frontline innovation
- Surgical leaders urged to weigh risks, rewards of innovation with a critical eye
- Health systems report dramatic nurse retention gains through residency, development programs
- Surgical innovation redefines what is possible for advanced colorectal cancer
- CMS proposal to end inpatient only list draws strong industry response
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement